0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Can we modify the course of migraine?

Session 4: Current strategies and the future ahead

Piero Barbanti

Associate Professor of Neurology - San Raffaele University, Rome, Italy Director, Headache and Pain Unit - IRCCS San Raffaele

Download presentation

Previous

Switching between anti-CGRP monoclonal antibodies and gepants

Next

Pregnancy management and breastfeeding in migraine

You Might Also Like

Related Embedded Video Item Thumbnail Children and adolescent as migraine patients - Diagnosis and management
Related Embedded Video Item Thumbnail Migraine preventative treatment recommendations/reimbursement conditions in the Nordics – What has changed in the last 5-6 years?
Related Embedded Video Item Thumbnail Burden of disease in children and adolescent
Related Embedded Video Item Thumbnail The role of inflammation in migraine and its clinical impact
Related Embedded Video Item Thumbnail Migraine management in elderly

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128